PURE Bioscience, Inc. (OTCMKTS:PURE – Get Free Report) saw a large decrease in short interest in August. As of August 15th, there was short interest totalling 77,300 shares, a decrease of 18.7% from the July 31st total of 95,100 shares. Based on an average trading volume of 15,700 shares, the days-to-cover ratio is currently 4.9 days.
PURE Bioscience Trading Down 10.0 %
PURE opened at $0.06 on Friday. The stock has a 50-day moving average of $0.07 and a 200-day moving average of $0.08. PURE Bioscience has a 52-week low of $0.06 and a 52-week high of $0.17.
PURE Bioscience (OTCMKTS:PURE – Get Free Report) last posted its quarterly earnings data on Friday, June 14th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.44 million during the quarter.
PURE Bioscience Company Profile
PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
Featured Stories
- Five stocks we like better than PURE Bioscience
- Stock Sentiment Analysis: How it Works
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- 3 Healthcare Dividend Stocks to Buy
- MarketBeat Week in Review – 8/26 – 8/30
- 5 Top Rated Dividend Stocks to Consider
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
